Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Bevespi Aerosphere on Exercise Tolerance in COPD
NCT03081156Phase 4Completed
- Start
- Mar 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of BEVESPI AEROSPHERE in chronic obstructive pulmonary disease (COPD) (2 arms). Primary endpoint: Change in Exercise Time During Cycle Ergometer Exercise. Started Mar 2017; status: completed.
02
Drugs
BEVESPI AEROSPHERE
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03081156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03081156.